[1]梁逸宁,杜贞华,王志龙,等.肾上腺动脉栓塞联合微波消融术治疗肾上腺转移瘤[J].介入放射学杂志,2022,31(11):1060-1064.
 LIANG Yining,DU Zhenhua,WANG Zhilong,et al.Adrenal artery embolization combined with microwave ablation in the treatment of adrenal metastatic tumors[J].journal interventional radiology,2022,31(11):1060-1064.
点击复制

肾上腺动脉栓塞联合微波消融术治疗肾上腺转移瘤()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年11
页码:
1060-1064
栏目:
肿瘤介入
出版日期:
2022-12-13

文章信息/Info

Title:
Adrenal artery embolization combined with microwave ablation in the treatment of adrenal metastatic tumors
作者:
梁逸宁 杜贞华 王志龙 林文俐 左太阳
Author(s):
LIANG Yining DU Zhenhua WANG Zhilong LIN Wenli ZUO Taiyang.
Department of Oncology Intervention, Affiliated Central Hospital of Shandong First Medical University, Jinan, Shandong Province 250013, China
关键词:
【关键词】 经导管动脉栓塞术、微波消融、肾上腺转移瘤、介入治疗
文献标志码:
A
摘要:
【摘要】 目的 了解经动脉栓塞术(transarterial embolization, TAE)联合微波消融术(microwave ablation,MWA)治疗肾上腺转移瘤的可行性、安全性、有效性。方法 回顾性分析2018年1月至2021年12月在山东第一医科大学附属中心医院介入科接受TAE同步联合MWA治疗的21例患者的临床资料。21例患者均经病理确诊为肾上腺转移瘤,均在TAE治疗后于CT引导下行经皮穿刺MWA,术后即刻行CT平扫,术后1、3、6个月及1年行腹部CT/MRI增强检查。随访期间记录患者的不良反应、并发症及生存时间。结果 TAE联合MWA的技术成功率为100%。仅有2例患者于术中出现高血压危象,1例患者出现肾上腺功能不全,其余患者仅出现一过性不良反应,对症治疗后均缓解。术后1、3、6个月及1年的完全缓解率分别为95.2%(20/21)、95.2%(20/21)、85.7%(18/21)、80.9%(17/21),部分缓解率分别为4.8%(1/21)、4.8%(1/21)、14.3%(3/21)、19.1%(4/21)。客观缓解率为100%。中位生存时间(OS)为32.5个月,12、18、24个月总生存率分别为100%、85.7%、66.7%。结论 TAE联合MWA是可行的,且安全有效,可用于治疗肾上腺转移瘤患者。

参考文献/References:

[1] Spartalis E, Drikos I, Ioannidis A, et al. Metastatic carcinomas of the adrenal glands: from diagnosis to treatment[J]. Anticancer Res, 2019, 39: 2699- 2710.
[2] Li Y, Ji Z, Wang D, et al. Bilateral adrenal metastasis of renal cell carcinoma 4 years after radical nephrectomy: a case report and review of literature[J]. Medicine(Baltimore), 2021, 100: e26838.
[3] Orzechowski S, Gnass M, Czyzewski D, et al. Ultrasound predictors of left adrenal metastasis in patients with lung cancer: a comparison of computed tomography,positron emission tomography- computed tomography, and endoscopic ultrasound using ultrasound bronc- hoscope[J]. Pol Arch Intern Med, 2022, 132: 16127.
[4] Mikulic D, Stironja I, Jadrijevic S, et al. Adrenalectomy for bilateral metachronous adrenal recurrence of hepatocellular carcinoma after liver transplant: a case report[J]. Exp Clin Transplant, 2020, 18: 407- 409.
[5] Kometani M, Yoneda T, Maeda Y, et al. Carcinoma of unknown primary origin with isolated adrenal metastasis: a report of two cases[J]. Endocr J, 2021, 68: 1209- 1215.
[6] 谢剑伟,杜 超,殷 波. 转移性肾上腺癌的临床治疗(附15例报告)[J]. 现代肿瘤医学, 2020, 28:1170- 1173.
[7] Staubitz JI,Clerici T,Riss P,et al. EUROCRINE?誖: adrenal surgery 2015- 2019- surprising initial results[J]. Chirurg, 2021, 92: 448- 463.
[8] Zuo T, Lin W, Liu F, et al. Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum[J]. BMC Cancer, 2021, 21: 505.
[9] Zuo TY, Liu FY, Wang MQ, et al. Transcatheter arterial chemo- embolization combined with simultaneous computed tomography- guided radiofrequency ablation for large hepatocellular carcinomas[J]. Chin Med J(Engl), 2017, 130: 2666- 2673.
[10] 曹昆昆,李晓伟,付志刚,等. 微波消融同步联合经导管动脉化疗栓塞治疗膈下肝细胞癌[J]. 中国介入影像与治疗学, 2021, 18:659- 662.
[11] 徐 圣,张学军,石宝琪,等. 微波消融联合经导管动脉化疗栓塞术治疗肝细胞癌生存预测[J]. 介入放射学杂志, 2020, 29:508- 513.
[12] 刘 毅,卓 琳,朱 蓓,等. 肝动脉化疗栓塞联合经皮消融治疗肝细胞癌疗效的meta分析[J]. 介入放射学杂志, 2017, 26:830- 835.
[13] Fujisaki A, Takayama T, Suzuki M, et al. Mechanism of hyper- tensive crisis during energy device ablation of the adrenal gland: an experimental animal study[J]. Int J Urol, 2021, 28: 598- 604.
[14] Kim MN, Kim BK, Han KH, et al. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment[J]. Expert Rev Gastroenterol Hepatol, 2015, 9: 335- 348.
[15] Nadeem IM, Sakha S, Mashaleh R, et al. Percutaneous image- guided radiofrequency ablation for adrenal tumours: a systematic review[J]. Clin Radiol, 2021, 76: 829- 837.
[16] Pan S, Baal JD, Chen WC, et al. Image- guided percutaneous ablation of adrenal metastases: a meta- analysis of efficacy and safety[J]. J Vasc Interv Radiol, 2021, 32: 527- 535.e1.
[17] Gao Y, Zheng L, Liang P, et al. Evaluating the efficacy and safety of ultrasound- guided percutaneous microwave ablation for the treatment of adrenal metastasis[J]. J Cancer Res Ther, 2020, 16: 1088- 1092.
[18] Park BK, Fujimori M, Shen SH, et al. Asian conference on tumor ablation guidelines for adrenal tumor ablation[J]. Endocrinol Metab(Seoul), 2021, 36: 553- 563.
[19] Ethier MD, Beland MD, Mayo- Smith W. Image- guided ablation of adrenal tumors[J]. Tech Vasc Interv Radiol, 2013, 16: 262- 268.
[20] Donlon P, Dennedy MC. Thermal ablation in adrenal disorders: a discussion of the technology, the clinical evidence and the future[J]. Curr Opin Endocrinol Diabetes Obes, 2021, 28: 291- 302.
[21] Li J, Li Z, Jiao DC, et al. Clinical outcomes after selective renal artery embolization combined with dynact- guided microwave ablation for T1 a renal- cell carcinoma:case series[J]. Clin Genitourin Cancer, 2021, 19: e1- e5.
[22] Kobe A,Tselikas L,Deschamps F, et al. Thermal ablation combined with selective transarterial embolization of centrally located renal cell carcinomas measuring 3 cm or larger[J]. Cardiovasc Intervent Radiol, 2022, 45: 371- 379.
[23] 李 臻,纪 坤,王彩鸿,等. 经导管动脉栓塞联合微波消融治疗肾癌的初步疗效分析[J]. 微创泌尿外科杂志, 2021, 10:118- 122.
[24] Fowler AM, Burda JF, Kim SK. Adrenal artery embolization: anatomy, indications, and technical considerations[J]. AJR Am J Roentgenol, 2013, 201:190- 201.
[25] 叶 欣.影像引导下肾上腺肿瘤消融治疗的严重并发症——高血压危象[J]. 中华医学杂志, 2019, 99:1121- 1122.
[26] 徐红豆,吴文涛,施海彬,等. 微波消融治疗肾上腺肿瘤致高血压危象1例[J]. 实用放射学杂志, 2021, 37:1735- 1736.
[27] Uppot RN, Gervais DA. Imaging- guided adrenal tumor ablation[J]. AJR Am J Roentgenol, 2013, 200: 1226- 1233.
[28] Zheng L,Zhou F,Yu X,et al. Hypertensive crisis during microwave ablation of adrenal neoplasms: a retrospective analysis of predictive factors[J]. J Vasc Interv Radiol, 2019, 30: 1343- 1350.
[29] Keeling AN, Sabharwal T, Allen MJ, et al. Hypertensive crisis during radiofrequency ablation of the adrenal gland[J]. J Vasc Interv Radiol, 2009, 20: 990- 991.
[30] 王 龙,卢 琳,陆召麟,等. 原发性肾上腺皮质功能减退症的病因构成及临床特点[J]. 中华医学杂志, 2020, 100:915- 921.

备注/Memo

备注/Memo:
(收稿日期:2022- 03- 16)
(本文编辑:新 宇)
更新日期/Last Update: 2022-12-09